Slides
Page 1
METROPOLIS HEALTHCARE LIMITED Q1FY26 INVESTOR PRESENTATION
Page 2
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. 1
Page 3
35 ISO:15189 Accredited Labs (31 in India / 4 in Kenya) 2 CAP Accredited Lab (India) 43+ years of credible experience 4,000+ Tests & Profiles 222 Clinical Labs 4,500+ Service Network Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand trusted by clinicians, patients and stakeholders. Positively impact the lives of patients in their most anxious times and turn their anxiety into assurance 11% CAGR revenue growth in last 7 years 2
Page 4
Performance & Company Updates – Q1FY26 3 MHL Group Key Financials (Page 4)01 MHL Organic Key Financials (Page 5)02 MHL Organic Patient & Test Volume Highlights (Page 7 & 8) 03 MHL Organic B2C Business Highlights (Page 9) 04 MHL Organic B2B Business Highlights (Page 10)05 MHL Organic Tru Health Business (Page 11)06 MHL Organic Speciality Business (Page 12)07 MHL Group Patient & Test Volume Highlights (Page 14) 08 09 MHL Group Network Highlights (Page 16)10 MHL Group P&L Statement (Page 17) 11 MHL Organic P&L Statement (Page 17) 12 MHL Group Highlights Geography wise (Page 15) Important Updates & Definitions: 1. MHL Group – Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra 2. MHL Organic – Excludes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra 3. Change of definition of B2C and B2B to standardize with the Industry practice. Accordingly previous period numbers are re -casted. • B2C now includes all own, franchisee and rural centres • B2B now includes B2B labs, Hospitals, Government, Corporate and Clinical Trial 4. Date of Consolidation of the Acquisitions • Core Diagnostics - 21st March 2025 • DAPIC, Dehradun - 23rd May 2025 • Scientific Pathology, Agra -16th June 2025
Page 5
Q1FY26 Key Financials – MHL Group • Revenue growth fueled by organic & recent acquisitions • Q1FY26, EBITDA margin at group level stood at 23. 1% • Core Diagnostics EBITDA Margins turned positive and is on a growth trajectory • EBITDA margins for DAPIC - Dehradun and Scientific Pathology - Agra continue to exceed the company’s average margin levels 4 INR 89 Cr +14% YoY EBITDA INR 45 Cr +19% YoY PAT INR 386 Cr +23% YoY Revenue MH L G r o u p – I n cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o gy – A gr a
Page 6
Q1FY26 Key Financials – MHL Organic • Organic revenue grew in double digits consistently, outpacing industry trends • Growth was driven by higher network productivity, scientific upselling, and micro -market - focused execution. • Q1FY26 EBITDA margin stood at 24.7 %, improving quarter -on - quarter • Margin expansion was supported by stronger operating leverage 5 INR 88 Cr +12% YoY EBITDA INR 46 Cr +21% YoY PAT INR 355 Cr +13% YoY Revenue MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o g y – A g r a
Page 7
6 Q1FY26 Key Performance Indicators MHL Organic Excludes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology - Agra
Page 8
Q1FY26 Key Performance Indicators • Patient and test volumes rebounded, with June recording 8% patient volume growth • Strong B2C revenue growth driven by intensified clinician and community engagement • B2B segment delivered double -digit growth despite pricing pressures, supported by report quality and service standards • Higher -end offerings in TruHealth and Genomics/AI testing in Specialty, accelerating strategic growth priorities INR 209 Cr +16% YoY B2C Revenue INR 64 Cr +22% YoY TruHealth INR 134 Cr +16% YoY Specialty INR 146 Cr +10% YoY B2B Revenue 3.2 Mn +7% YoY Patient Volume 6.8 Mn +8% YoY Test Volume 7 M H L O r g a n i c – E x c l u de s r e c e n t a c q u i s i t i o n s o f C or e D i ag n o s t i c s , D A P I C - D e h r ad u n an d S c i en t i f i c P a t h o l o g y – A g r a B 2 C n o w i n c l u d e s a l l o w n , f r an c h i s ee a n d r u r a l c e n tr e s ; B 2 B n o w i n c l u d e s B 2 B l a b s , H o s p i t a l s , G o v er n m en t , C o r p o r at e a n d C l in ic al T r i a l
Page 9
Consistently Delivering Patient & Test Volume Growth Patient Volume (in Mn) Test Volume (in Mn) Revenue Per Patient (RPP) INR Revenue Per Test (RPT) INR 9.7% 8 6% 7% 8% 1,035 1,098 Q1FY25 Q1FY26 6% o Revenue per patient grew 6% YoY, driven by a better mix and higher-end test upselling o Growth was led by increased contribution from TruHealth and Specialty segments, aligning with our high-value focus o Improved tests per patient through scientific upselling and recommendation engine strengthened both RPT and revenue quality 17% 27% 38% 18%Routine Semi-Special Specialty Q1FY26 Segment Contribution TruHealth 22% 16% 8% 8% TruHealth Specialty Semi-Special Routine Q1FY26 Segment Revenue Growth 3.03 3.23 Q1FY25 Q1FY26 6.28 6.79 Q1FY25 Q1FY26 499 523 Q1FY25 Q1FY26 5% MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o gy – A gr a
Page 10
Strong B2C revenue growth @ 16% YoY B2C Contribution B2C Revenue (Maharashtra) B2C Specialty B2C TruHealth • B2C patient volume grew 9%, with a 6% increase in revenue per patient, driven by high - value scientific upselling • B2C TruHealth and Specialty segments led growth, powered by new test additions and our Next Best Action engine • App adoption and engagement improved, through personalised journeys and real -time tracking • Micro -marketing, clinician engagement, and the Metlink partner programme enabled deeper local market penetration 9 +16% +18% +19% 59% (+120bps) MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c P a th o l o g y – A g r a B 2 C n o w i nc l u d e s a l l o w n , f r a n ch i s e e a n d r u r a l c e nt r e s ; B 2 B n o w i n cl u d e s B 2 B l a b s, H o s p i t a l s, G o v e r n m e n t, Co r p o r a t e a n d Cl i ni c a l T r i a l
Page 11
B2B revenue growing by 10% YoY B2B Revenue B2B Specialty B2B TruHealth +10% +15% +46% 10 B2B Contribution 41% • B2B patient volumes grew 4%, with a 6% rise in RPP, supported by hospital -led high -value outsourcing • Clinical trial business, delivered strong contribution, aligning with our specialty focus • Corporate partnerships and outreach initiatives expanded engagement • Partner portal upgrades improved transparency, tracking, and service resolution across segments M H L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c P a th o l o g y – A g r a B 2 C n o w i nc l u d e s a l l o w n , f r a n ch i s e e a n d r u r a l c e nt r e s ; B 2 B n o w i n cl u d e s B 2 B l a b s, H o s p i t a l s, G o v e r n m e n t, C o r p o r a t e a n d C l i ni c a l T r i a l
Page 12
TruHealth Revenue grew @ 22% YoY for Q1FY26 11 18% Revenue Contribution 22% Growth o Strong Revenue and Volume Momentum with high-end integrated packages underscoring successful premium positioning • ~1.5X revenue growth QoQ from premium TruHealth wellness packages integrated with home-based ECG, vital checks, and consultations • Contribution to overall wellness volumes doubled in the same period—driven by consumer preference for end-to-end preventive health solutions • Radiology-Integrated Packages Gained Traction - 1.6X QoQ growth in revenue o AI-Driven Personalization Enhancing Conversion • MetAdvisor, our AI-powered recommendation engine, saw 2.5X increase in adoption, leading to higher conversion rates through scientifically validated cross-sell and upsell o Hyperlocal Micro-Marketing Driving Regional Uptake • Leveraged granular insights to curate regional TruHealth variants, aligning with local health needs and unlocking growth in underpenetrated zones MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o gy – A gr a
Page 13
Speciality Revenue grew @ 16% YoY for Q1FY26 12 Specialty 38% Revenue Contribution 16% Growth o Innovation-Led Launches with Market Differentiation • Launched Hereditary Cancer Panel and new bundled Onco-360 profiles as preventive screening. Expanded Neurological Portfolio with new tests for disease segments o AI-based and assisted testing • Significant take-up of AI-powered Prostate Cancer Test for accurate diagnosis and AI- driven Karyotyping o NGS Growth Backed by Scientific Engagement • NGS segment delivered robust growth, led by an expanded Oncology & Reproductive test menu, sales incentive schemes, and sustained scientific engagement with clinicians o Clinician Engagement Driving Rx Growth • 100+ CME/RTM events in Q1 boosting awareness and Rx • MSL optimization helped sharpen focus on key accounts, increasing specialty Rx and penetration • Sales training and medical education boosted growth in Neuro-genomics & Transplant portfolios MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o g y – A g r a
Page 14
13 Q1FY26 Key Performance Indicators MHL Group Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra
Page 15
Q1FY26 Key Performance Indicators INR 214 Cr +19% YoY B2C Revenue INR 546 +10% YoY RPT INR 1,151 +11% YoY RPP INR 172 Cr +29% YoY B2B Revenue 3.4 Mn +11% YoY Patient Volume 7.1 Mn +12% YoY Test Volume 14 17% 27% 39% 17% Routine Semi-Special Specialty Q1FY26 Segment Contribution TruHealth 24% 32% 13% 20% TruHealth Specialty Semi-Special Routine Q1FY26 Segment Revenue Growth 14 MH L G r o u p – I n cl u d e s recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra
Page 16
Diversified Revenue contribution across Geographies Map not to scale and for illustrative purpose only 27% 5% 17% 52% By Region (MHL Categorisation) Presence in ~750 towns Network expansion leading to revenue growth of ~17% from Tier III cities Focused expansion into UP, MP, AP&TS, Assam help move wider into newer geographies South East North 68% 7% 25 % By City Tier Tier I Tier II Tier III 15 Revenue Contribution Revenue Contribution Revenue Contribution of Domestic Revenue only West 56% 24% 20% By Cities (MHL Categorisation) Focus Seeding Others Revenue Contribution MH L G r o u p – I n cl u d e s recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra Contribution from North India has increased to 17% 17% 65% 13% Others Seeding Focus 17% 10% 27% T3 T2 T1 Revenue Growth Revenue Growth 30% 5% 9% 56% Revenue Contribution Q1FY25 Q1FY26 Q1FY26 Q1FY26
Page 17
Network Expansion – Robust expansion with consolidation laying strong base 255 260 251 325 327 431 531 565 1,506 1,873 1,806 2,105 2,594 2,914 3,135 3,161575 598 498 704 754 805 870 890 FY19 FY20 FY21 FY22 FY23 2,336 2,731 2,555 3,134 3,675 Rural Franchisee Owned Service Network *including 20 labs of Hi-tech acquired in FY22 +2,061 Centres ~750 towns from 300 towns in FY23 12 Labs added in Q1 FY26 Including acquired labs 80 Centres added in Q1 FY26 Including acquired Centers FY24 4,150 16 4,536 FY25 119 124 125 161 175 199 210 222 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Laboratory Network Q1FY26 +97 Labs Q1FY26 4,616 MH L G r o u p – I n cl u d e s recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra
Page 18
Q1 FY26 Profit & Loss Statement 17 Profit & Loss Statement (Rs. Crs.) Q1FY25 Q1FY26 (MHL Organic) Y-o-Y Revenue from Operations 313.4 354.8 13.2% Total Cost 235.2 267.2 Reported EBITDA 78.2 87.5 11.9% Reported EBITDA (%) 25.0% 24.7% Depreciation 25.5 29.1 Other Income 2.5 7.4 EBIT 55.1 65.8 19.4% Finance Cost 4.0 3.7 Profit Before Tax 51.1 62.1 21.6% Current Tax 13.0 15.9 Profit After Tax 38.1 46.2 21.2% PAT Margin (%) 12.2% 13.0% Q1FY26 (MHL Group) Y-o-Y 386.1 23.2% 296.9 89.1 14.0% 23.1% 30.8 7.5 65.8 19.4% 4.6 61.2 19.9% 16.0 45.2 18.7% 11.7% MH L G r o u p – I n cl u d e s recent acquisitions of Core Diagnostics, DAPIC - Dehradun and Scientific Pathology – Agra MH L O r g a n i c – E x cl u d e s r e ce n t a cq ui s i t i o n s o f Co r e D i a g n o st i c s, D A PI C - D e h r a d u n a nd S c i e nt i f i c Pa t h o l o g y – A g r a
Page 19
Metropolis 3.0
Page 20
Key Pillars of Metropolis 3.0 Strategy – poised to grow further Strengthening the Core Expand to Adjacencies while Forging New AlliancesExpand market share in core and new geographies with focus on specialized and wellness testing, strengthening Top 800 towns via Micro Market Strategy, T3 Acceleration, and breakthrough asset productivity. Build a differentiated Brand and enhance customer experience through consistent & superior touchpoint experience Expand into adjacencies such as complementary radiology and primary healthcare, while driving new initiatives like excellence in Genomics and other emerging high-science domains. Fostering Sustainability Bolt On Acquisition Enhance compliance and solidify governance, while prioritizing impactful ESG initiatives and social responsibilities to maximise shareholder value Drive new market expansion and build synergies through seamless integration of all acquired assets. Widen reach in priority geographies, with focused acceleration in UP, AP & T, East & North 1 2 4 3 3. Target a Revenue CAGR of mid-teen from FY23 to FY26 Achieve Pre-Covid Margin Profile Be the fastest growing Diagnostics Company within the National Chains Segment 19
Page 21
Enhanced Productivity Second generation Point of Sale Platform Registration and Invoicing Platform 2.0 Rapid Scalability Community Cloud for better life-cycle management Future Ready Architecture and AI Enablement Customer Data Platform for 360- degree customer view and using AI to personalize experiences Improved User Experience Sales CRM with customizable CPQ to manage dynamic pricing Driving business growth through Digital Transformation Business Continuity & Agility Metropolis is a unique Healthcare Company equipped with CDP, Marketing Cloud, Service Cloud, Sales Cloud, Community Cloud PersonalizationCross Channel Consistency Efficient Patient Service Case Management Relationship Management Opportunity Management Enhanced Security Efficient Patient Registration Accurate Billing & Pricing Reporting & Analysis 360- Degree Customer View 20
Page 22
Scientifically driven with strong focus on quality, research and academics UGC Certified MedTech courses started with University Collaboration New Tests added in Q1FY26 (including CDP) and 60+ tests in FY25 EQAS (External Quality Assurance Score) Top SME doctors in internal Medical Advisory Board to augment scientific information 50+ 48+ 99% 8+ Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven by in-house testing and automated genetic test reporting Metropolis Institute of Laboratory Education and Skilling • Med-tech Courses introduced for doctors & technologists in collaboration with reputed institutions • Alignment with government focus on upskilling and development of trained workforce Innovation & Quality • Launched AI-verified prostate biopsy tests and AI Karyotyping • Simplified Smart Reports and data-driven Next Best Action initiatives for chronic patients, along with strategic clinician engagement and POCT deployment for remote areas • Quantifying quality of all labs through Quality index & star rating i-MAB – internal Medical Advisory Board • SME i-MABs with over 50 subject matter experts focusing on scientific enhancement including internal clinical academic enrichment and quality improvement • Centres of Excellence pipeline on 3 specialties 21 100% Labs either CAP, NABL, KENAS accredited or benchmarked against same 100% MHL Labs are verified by External Quality Assurance programs (EQAS/PT) 99.999% Report accuracy 1st Lab to launch Next Best Action for Chronic disease management Center of Excellence: Women & child health & Oncology. Building cutting edge capabilities in Molecular Genomics
Page 23
Metropolis ESG’ Goals Well identified ESG Focus Areas and assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. Emission Goals for a Greener Tomorrow Achieving Zero Waste and Water Neutrality by 2043 Fostering Quality, Safety, Diversity and Community Well-being Upholding Integrity, Security, and Compliance • Carbon Neutrality by 2043 • 45% reduction in emissions intensity by 2030 • Zero waste in offices by 2030 • Reduce plastic usage by 50% by 2030. • Reduction of water intensity by 30% by 2030 • B2C NPS @90 by 2028 • 100% awareness & training on OHS • Gender-neutral workforce by 2028 • Impact lives of 6 lakh direct beneficiaries by 2043 • Maintain zero data breaches • Data protection and patient privacy: ISO 27001 & ISO 27701 • Zero instances of non-compliances e s g 22
Page 24
Emissions & Energy Water & Waste Management Employee Recruitment, Development and Retention Occupational Employee Health & Safety Patient Privacy and Electronic Health Records Community Development Risk Management Quality of Care and Patient Satisfaction Board Governance, Ethics and Compliance • Achieve 10% reduction in energy consumption through renewable energy • Implement sub-metering solutions. • Replace end-of-life assets to improve efficiency. • Reduce air miles by 2% • Achieve 5% reduction in water usage through conservation • Implement rainwater harvesting. • Achieve zero e-waste through buyback methods. • Reduce plastic usage by 10% with biodegradable alternatives. • MedEngage, Too Shy to Ask (TSTA) and Preventive Healthcare CSR projects • Career 2.0 Campaign to increase gender diversity • Strengthen learning and development programmes • Reduce attrition through Early Warning Signals • Raise awareness on safety among employees • Safety audits for compliance check • Annual assessments of Risk Register according to ERM • Track mitigation plans for identified high-risk areas. • 100% training on information security and data privacy. • Sustenance audits by BSI to maintain ISO 27001 and ISO 27701 certifications. • Aim for B2C NPS score over 90% by addressing detractors • Resolve over 85% of complaints within 24 hours • Inclusion and ongoing amendment of policies and processes from Corporate law and organization perspective • Zero instances of non-compliance • Board diversity Key ESG Plans 23
Page 25
Too Shy to Ask(TSTA) • TSTA Rural focusing on adolescent reproductive and sexual health, and life skills. and reached 1 lakh+ • 4000 action plans made by adolescents girls . • 3000 external stakeholders oriented on ARSH as key influencers CSR at Metropolis – creating a positive impact • 365 Scholarships supported the with MedEngage scholarship support. including research grants. • Research Grant grew to 50% (43 Research Grant from previous Fy year . • Regular MedTalk and webinars with SMEs for grooming young medical talent . Reached 1 lakhs views Preventive healthcare Project • 1000 TB patients to receive nutritional support in FY25 to ensure medication adherence. • Focus on non-communicable diseases like diabetes and Anemia, with an estimated outreach of 3 lakh individuals. • 89% of the beneficiaries have appreciated the Programme 24 MedEngage
Page 26
‘Promoter led – Professionally driven’ organisation Ameera Shah Promoter & Executive Chairperson Surendran Chemmenkotil Managing Director Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah President - Internal Assurance Dr. Sushil Shah Founder & Non – Executive Non - Independent Director Kannan Alangadan Chief Business Officer South Dr. Kirti Kazi Chief Scientific & Innovation Officer and Group Head CSR Avadhut Joshi Chief Business Development Officer Mohan Menon Chief Marketing Officer Bhoopendra Rajawat Chief Business Officer West & North and East 25 Pinakin Shah Chief Information Officer Diya Suri Chief People Officer Sameer Patel Chief Financial Officer
Page 27
Recent Awards and Accolades 26 Jun’25 Metropolis Healthcare – Most Innovative Organizations Award by ET Now for the year 2025 Jun’25 Metropolis Healthcare – Best Healthcare Brands Award by ET Edge for the year 2025 Jun’25 Metropolis Healthcare - Gold Award for Best Diagnostic Chain of the Year 2025 at the FE Healthcare Excellence Awards Jun’25 Ameera Shah – Most Powerful Woman in Business by Fortune India for the year 2025 Mar’25 Ameera Shah – Most Influential Women in India 2025 by Business World Feb’25 Metropolis Healthcare – WOW Workplace Award for the year 2025 in the Pharmaceutical and Healthcare category Nov’24 Ameera Shah – Most Powerful Women in Business by Business Today for the year 2024 Sept’24 Ameera Shah - Healthcare Icon/Leader of the Y ear Award at the ET Healthcare Excellence Awards 2024 Jul’24 Gold Award for Best Content Marketing & Bronze Award for Best Social Media Communication at E4M Health & Wellness Marketing Awards 2024 Apr’24 Gold Award - Diagnostic Chain of the Y ear and Bronze Award - Best CSR Practice in Healthcare at the FE Healthcare Excellence Awards 2024 Mar’24 CSR Program MedEngage - Winner at the 3rd edition of the NATHealth Impact Awards 2024 in the CSR category Feb’24 Dr Sushil Shah - Lifetime Achievement in Diagnostics Leadership Award by Voice of Healthcare at the Diagnostic Innovation and Excellence Awards 2024 Oct’23 Metropolis Foundation - 'Too Shy to Ask’ (TSTA) CSR Program - Best Sex Education Initiative of the Year Award at the Indian CSR Awards 2023 Aug‘23 Best Diagnostic Company Award (Winner) and the Best CSR Excellence in Healthcare Award (1st Runner Up) at ASSOCHAM’s 2nd Healthcare Summit and Awards
Page 28
Company : Investor Relations Advisors : Metropolis Healthcare Ltd. CIN – L73100MH2000PLC192798 Mr. Kamlesh Kulkarni Email Id – secretarial@metropolisindia.com www.metropolisindia.com Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91 77383 77756 / +91 98205 19303 www.sgapl.net For further information, please contact: http://www.sgapl.net/images/sgapl_logo.jpg 27